Nasdaq’s Amgen swoops for Dark Blue Therapeutics in 拢622m deal
Nasdaq-listed Amgen has agreed to acquire Oxford-based Dark Blue Therapeutics in a deal valued at around 拢622 million. The swoop is set to strengthen the US MedTech giant鈥檚 early-stage oncology pipeline and its focus on targeted protein degradation. Private firm Dark Blue Therapeutics is currently developing first-in-class small molecule therapies designed to degrade disease-driving proteins.聽 … Continue reading Nasdaq’s Amgen swoops for Dark Blue Therapeutics in 拢622m deal
